๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.3 Merck Sharp & Dohme LLC2 Bayer2 Beijing Geekgene Technology Co., LTD2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Trials with a site in Beijing

54 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors
NCT07750132Advanced Solid Tumors
Beijing StarMab Biomed Technology Ltd
Phase 1
72
Beijing
2026-09-20
Recruiting
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
NCT07700160Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
230
Beijing, Shanghai, Hangzhou
2026-07-30
Not yet open
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
NCT07738679Advanced Solid Tumors
DrugTQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
NCT07412665Advanced Solid Tumors
DrugGK01
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1
10
Beijing
2026-06
Recruiting
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
NCT07648472Advanced Solid Tumors
DrugOVV-01
Joint Biosciences Ltd.
Phase 1
18
Beijing
2026-04-21
Not yet open
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
NCT07482319Advanced Solid Tumors
DrugGK01
Beijing Geekgene Technology Co., LTD
Phase 1
15
Beijing
2026-04
Active, closed
Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection
NCT07826585Advanced Solid Tumors
Corregene Biotechnology Co., Ltd
Phase 1
6
Beijing
2026-03-26
Recruiting
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT07561437Advanced Solid Tumors
DrugNK521 Cell
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Beijing
2026-03-09
Recruiting
SKB105 for Injection in Advanced Solid Tumors
NCT07380386Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
256
Beijing, Shanghai
2026-03-05
Recruiting
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
NCT07328217Advanced Solid Tumors
DrugGW5282
Dizal Pharmaceuticals
Phase 1/2
203
Beijing
2026-01-29
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
NCT07349160Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2026-01-10
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
NCT07359066Advanced Solid Tumors, PARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Beijing, Harbin
2026-01-08
Not yet open
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
NCT07275853Advanced Solid Tumors
DrugKXV01 TCR Lentinvivo
TCRx Therapeutics Co.Ltd
Phase 1
30
Beijing
2025-12-01
Recruiting
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
NCT07253116Advanced Solid Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2
20
Beijing
2025-11-20
Recruiting
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
NCT07208136Advanced Solid Tumors
Jemincare
Phase 1
102
Beijing
2025-10-22
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
DrugBMS-986504
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
NCT06998173Advanced Solid Tumors
Danatlas Pharmaceuticals Co., Ltd
Phase 1
228
Beijing
2025-07-31
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Not yet open
Allogeneic B7H3 CAR-ฮณฮดT Cell Therapy for Advanced Solid Tumors
NCT06825455Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer
DrugsFludarabine·Cyclophosphamide
Peking University
Phase EARLY_PHASE1
18
Beijing
2025-03-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
Drugs5-FU·Leucovorin·Irinotecan·Etoposide
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091Advanced Solid Tumors
DrugsNK042·Fludarabine·Cyclophosphamide
Shanghai NK Cell Technology Co., LTD
Phase 1
76
Beijing
2025-02-07
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
NCT06770569Advanced Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1
100
Beijing
2025-01-21
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study of SIGX1094R in Patients With Advanced Solid Tumors
NCT06739291Advanced Solid Tumors
Signet Therapeutics
Phase 1
102
Beijing
2024-12-12
Not yet open
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828Advanced Solid Tumors
DrugSHR-4602
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-12
Active, closed
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
NCT06610227Advanced Solid Tumors
NING LI
Phase EARLY_PHASE1
18
Beijing
2024-11-08
Recruiting
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT06598735Advanced Solid Tumors
DrugHRS-4508
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
290
Beijing
2024-11-05
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970Advanced Solid Tumors
DrugMRG006A
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Recruiting
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554Advanced Solid Tumors
DrugsSHR-A2102·Disitamab Vedotin·Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
80
Beijing
2024-05-27
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
DrugSerplulimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Recruiting
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580Malignant Melanoma, Advanced Solid Tumors
DrugAMT-253
Multitude Therapeutics Inc.
Phase 1/2
96
Beijing
2024-01-31
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Bevacizumab·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Not yet open
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
NCT06183736Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420Advanced Solid Tumors
DrugsFruquintinib·Docetaxel·Bevacizumab·Paclitaxel
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
DrugsINCA33890·ADG126·Folfiri·Folfox
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Recruiting
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
NCT05773820Advanced Solid Tumors
DrugWJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
210
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Recruiting
Phase 1 Trial of KH617
NCT05667194Advanced Solid Tumors
Sichuan Honghe Biotechnology Co., Ltd.
Phase 1
45
Beijing
2022-12-26
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
DrugHRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

39 of the 54 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 54 studies
PhaseStudiesRecruitingShare
Phase 1281951.9%
Phase 1/2171731.5%
Phase EARLY_PHASE1529.3%
Phase 2417.4%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Jiangsu HengRui Medicine Co., Ltd.33
Bayer21
Beijing Geekgene Technology Co., LTD20
MediLink Therapeutics (Suzhou) Co., Ltd.21
Merck Sharp & Dohme LLC22
Shanghai Hengrui Pharmaceutical Co., Ltd.21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.22
AbbVie10
AskGene Pharma, Inc.11
Base Therapeutics (Shanghai) Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.